Oral Peanut Allergy Tx OK'd
This story was originally published on Jan. 31, 2020. As part of MedPage Today 's review of the past year's top stories, we are republishing it, along with an update on peanut allergy therapies and related developments as the year went on. WASHINGTON -- Aimmune Therapeutics' oral immunotherapy for peanut allergy gained FDA approval late Friday, for treating individuals age 4-17, the agency said. To be sold as Palforzia, the product consists of purified peanut proteins, to be administered in carefully controlled escalating doses. The approval comes with a mandatory Risk Evaluation and Mitiga...
Source: medpagetoday.com